Uncompetitive Allosteric Inhibition of PTP1B by BP-1-102 Reveals a Potential Dual-Target Strategy toward the PTP1B–STAT3 Oncogenic Axis: Biochemical and Computational Evidence
Open Access
- 12 June 2026
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1440-1447
Abstract
Selective PTP1B inhibitors paradoxically potentiate oncogenic STAT3 signaling by restoring JAK2 activity, underscoring the need for dual-target strategies. Here we report that BP-1-102, an orally bioavailable STAT3 SH2 domain inhibitor, also potently inhibits PTP1B with IC50 values of 5.32 μM (hPTP1B1–400) and 11.7 μM (hPTP1B1–285), with ≥37.7-fold selectivity over TCPTP. Kinetic analysis identified an uncompetitive mechanism, suggesting inhibitor binding to the enzyme–substrate complex at a site distal to the active site. Docking and 500 ns molecular dynamics simulations revealed a dual-anchor binding mode involving the 113–123 loop (Cys121) and the proline-rich C-terminal disordered region, a structural interface absent in TCPTP. Umbrella sampling confirmed favorable passive membrane permeability through a tumor-mimetic bilayer (ΔG = −13.83 kcal/mol). These results propose BP-1-102 as a candidate for dual-function inhibitor of the PTP1B–JAK2–STAT3 oncogenic axis, providing a physicochemical and mechanistic rationale for its further evaluation in tumors where both targets are coactivated.Keywords
Funding Information
- Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (PAPIIT-AV200225)
- Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (PAPIIT-IN205326)
- Research Division of the Medical School, UNAM (FM/DI/150/2025)
- Dirección General de Cómputo y de Tecnologías de Información y Comunicación, UNAM (LANCAD-UNAM-DGTIC-313)
This publication has 38 references indexed in Scilit:
- STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapiesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025
- Uncovering the individual immunotherapeutic roles of PTPN1 and PTPN2 in T cells during dual inhibitioniScience, 2025
- Impact of C18 Epimerization of Indole‐ and Pyrazole‐Fused 18β‐Glycyrrhetinic Acid Derivatives on PTP1B and TCPTP Inhibitory Activity: Synthesis, In Vitro, and In Silico StudiesChemMedChem, 2025
- Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugsFEBS Letters, 2024
- Recent updates on development of protein-tyrosine phosphatase 1B inhibitors for treatment of diabetes, obesity and related disordersBioorganic Chemistry, 2022
- Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discoveryMedicinal Research Reviews, 2021
- Selective Covalent Inhibition of “Allosteric Cys121” Distort the Binding of PTP1B Enzyme: A Novel Therapeutic Approach for Cancer TreatmentCell Biochemistry and Biophysics, 2019
- Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironmentArchives of Pharmacal Research, 2016
- Protein-tyrosine phosphatase 1B substrates and metabolic regulationSeminars in Cell & Developmental Biology, 2015
- PTP1B: a double agent in metabolism and oncogenesisTrends in Biochemical Sciences, 2010